MarketBeat
27 Sept 2026, 22:02 UTC · 15h ago
Verdict
Headline takes no side. We score EQ +0.40 across four claims — moderately bullish.
+0.40moderately bullish
More positive than 67% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 3 new · 1 priced in
Equillium plans to begin first-subject dosing in a Phase I study of EQ504 for ulcerative colitis during the fourth quarter.
Newannounced during a fireside chat
More positive than 93% of claims this week
Dosing the first subject of the EQ504 study is tied to a potential additional $20 million financing tranche from investors.
New
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatThis would increase total available capital to $77.2 million if the tranche is triggered in Q4.
More positive than 87% of claims this week
Equillium expects to move its celiac disease program, EQ302, toward the clinic within 12 to 18 months.
Newannounced during a fireside chat
So whatThis puts the potential Phase I entry for EQ302 in the first half of 2028.
More positive than 66% of claims this week
Equillium reported cash and equivalents of $57.2 million at the end of its most recent quarter.
Priced inreported at the end of most recent quarter
So whatThe company states this amount is sufficient to complete the Phase I study of EQ504.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 67% of ticker scores this week
The company provided detailed progress updates on its pipeline, planned Phase I study for EQ504, and a stable cash position.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
—
EQ hasn't traded since this ran. Last close $1.67 (Sep 25); the reaction starts at the next open.
EQ chart →
